{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:59:19Z","timestamp":1780750759752,"version":"3.54.1"},"publisher-location":"New York, NY","reference-count":21,"publisher":"Springer US","isbn-type":[{"value":"9781071647295","type":"print"},{"value":"9781071647301","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-1-0716-4730-1_10","type":"book-chapter","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:59:44Z","timestamp":1753707584000},"page":"157-162","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping"],"prefix":"10.1007","author":[{"given":"Rika","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"2","key":"10_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5435\/00124635-200203000-00009","volume":"10","author":"M Sussman","year":"2002","unstructured":"Sussman M (2002) Duchenne muscular dystrophy. J Am Acad Orthop Surg 10(2):138\u2013151","journal-title":"J Am Acad Orthop Surg"},{"issue":"363","key":"10_CR2","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/bmj.2.363.541","volume":"2","author":"Duchenne","year":"1867","unstructured":"Duchenne (1867) The pathology of paralysis with muscular degeneration (Paralysie Myosclerotique), or paralysis with apparent hypertrophy. Br Med J 2(363):541\u2013542","journal-title":"Br Med J"},{"issue":"3","key":"10_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"JJ Lee","year":"2013","unstructured":"Lee JJ, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3(3):144\u2013176. https:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"issue":"7","key":"10_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/jhg.2016.28","volume":"61","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Fueki N, Shiba N et al (2016) Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet 61(7):663\u2013667. https:\/\/doi.org\/10.1038\/jhg.2016.28","journal-title":"J Hum Genet"},{"issue":"4","key":"10_CR5","first-page":"498","volume":"45","author":"M Koenig","year":"1989","unstructured":"Koenig M, Beggs AH, Moyer M et al (1989) The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 45(4):498\u2013506","journal-title":"Am J Hum Genet"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2016.152","volume":"62","author":"A Nakamura","year":"2016","unstructured":"Nakamura A, Shiba N, Miyazaki D et al (2016) Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet 62:459. https:\/\/doi.org\/10.1038\/jhg.2016.152","journal-title":"J Hum Genet"},{"issue":"16","key":"10_CR7","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10_CR8","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. https:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JND-150113","volume":"3","author":"M Rodrigues","year":"2016","unstructured":"Rodrigues M, Echigoya Y, Fukada S et al (2016) Current translational research and murine models for Duchenne muscular dystrophy. J Neuromuscul Dis 3(1):29\u201348","journal-title":"J Neuromuscul Dis"},{"issue":"9","key":"10_CR10","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y et al (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"10_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"10_CR12","first-page":"1314","volume":"7","author":"X Yu","year":"2015","unstructured":"Yu X, Bao B, Echigoya Y et al (2015) Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res 7(8):1314\u20131331","journal-title":"Am J Transl Res"},{"key":"10_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_17","journal-title":"Methods Mol Biol"},{"issue":"3","key":"10_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KR Lim","year":"2017","unstructured":"Lim KR, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"10_CR16","doi-asserted-by":"publisher","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4). https:\/\/doi.org\/10.3390\/jpm7040013","DOI":"10.3390\/jpm7040013"},{"issue":"13","key":"10_CR17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.4155\/fmc.15.116","volume":"7","author":"A Guncay","year":"2015","unstructured":"Guncay A, Yokota T (2015) Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold? Future Med Chem 7(13):1631\u20131635. https:\/\/doi.org\/10.4155\/fmc.15.116","journal-title":"Future Med Chem"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","volume":"25","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Lim KRQ, Trieu N et al (2017) Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy. Mol Ther 25:2561. https:\/\/doi.org\/10.1016\/j.ymthe.2017.07.014","journal-title":"Mol Ther"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A et al (2011) Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1:34. https:\/\/doi.org\/10.1186\/2044-5040-1-34","journal-title":"Skelet Muscle"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s10038-017-0400-0","volume":"63","author":"T Shimo","year":"2018","unstructured":"Shimo T, Hosoki K, Nakatsuji Y et al (2018) A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR\/Cas9 and evaluation of antisense-mediated exon skipping. J Hum Genet 63:89\u201392","journal-title":"J Hum Genet"},{"issue":"3","key":"10_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1534\/g3.114.015834","volume":"5","author":"L Vouillot","year":"2015","unstructured":"Vouillot L, Thelie A, Pollet N (2015) Comparison of T7E1 and surveyor mismatch cleavage assays to detect mutations triggered by engineered nucleases. G3 (Bethesda) 5(3):407\u2013415. https:\/\/doi.org\/10.1534\/g3.114.015834","journal-title":"G3 (Bethesda)"}],"container-title":["Methods in Molecular Biology","Exon Skipping and Inclusion Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4730-1_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:06:12Z","timestamp":1780747572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4730-1_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9781071647295","9781071647301"],"references-count":21,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4730-1_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"29 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}